Transverse Cerebellar Diameter and Abdominal Circumference Ratio Versus Mid-Thigh Circumference and Femur Length Ratio in Assessment of Gestational Age in Normal and Growth Restricted Fetuses

June 23, 2026 updated by: Nora Abdallah Hassan Abdallah, Tanta University
The aim of this research was to examine the accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) and mid-thigh circumference and femur length (MTC/FL) in estimating the gestational age of healthy and abnormally growing fetuses.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Fetal growth restriction (FGR) is poor fetal growth, typically defined by weight under the 10th percentile, due to maternal, placental, and fetal factors.

The transcerebellar diameter to abdominal circumference ratio (TCD/AC) in ultrasound aids in predicting FGR, mainly through abdominal circumference (AC), while transverse cerebellar diameter (TCD) is less often related to fetal growth issues.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • El-Gharbia
      • Tanta, El-Gharbia, Egypt, 31527
        • Tanta University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This prospective study was conducted on 100 pregnant cases at the department of Obstetrics of Tanta University Hospital.

Description

Inclusion Criteria:

  • Pregnant women aged 18 to 35 years old.
  • 24-28 weeks of gestation
  • Primigravida
  • Single viable fetus
  • Reliable Last Menstrual Period (LMP) or first trimester ultrasonography to confirm gestational age.

Exclusion Criteria:

  • Chromosomal abnormalities.
  • Any medical disease that affect fetal growth.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A
Pregnant women with normal fetal growth.
Device: Fetal Ultrasound Assessment
All enrolled pregnant women underwent a standardized obstetric ultrasound examination between 24 and 28 weeks of gestation.
Group B
Pregnant women suffering from intrauterine growth restriction (IUGR).
Device: Fetal Ultrasound Assessment
All enrolled pregnant women underwent a standardized obstetric ultrasound examination between 24 and 28 weeks of gestation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) ratio
Time Frame: At the time of ultrasound examination (24-28 weeks of gestation)
Assessment of the diagnostic performance of the transcerebellar diameter to abdominal circumference ratio (TCD/AC) in predicting intrauterine growth restriction (IUGR)
At the time of ultrasound examination (24-28 weeks of gestation)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

October 1, 2024

Study Completion (Actual)

October 1, 2024

Study Registration Dates

First Submitted

June 23, 2026

First Submitted That Met QC Criteria

June 23, 2026

First Posted (Actual)

June 30, 2026

Study Record Updates

Last Update Posted (Actual)

June 30, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 36264MS311/9/23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

IPD Sharing Time Frame

After the end of study for one year.

IPD Sharing Access Criteria

The data will be available upon a reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gestational Age

Clinical Trials on Fetal Ultrasound Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe